{"id":68091,"date":"2026-06-12T20:20:17","date_gmt":"2026-06-12T12:20:17","guid":{"rendered":"https:\/\/flcube.com\/?p=68091"},"modified":"2026-06-12T20:20:18","modified_gmt":"2026-06-12T12:20:18","slug":"creaternas-my008211a-becomes-chinas-first-home-grown-oral-cfb-inhibitor-approved-for-paroxysmal-nocturnal-hemoglobinuria","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68091","title":{"rendered":"Createrna&#8217;s MY008211A Becomes China&#8217;s First Home-Grown Oral CFB Inhibitor Approved for Paroxysmal Nocturnal Hemoglobinuria"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Wuhan Createrna Science and Technology Co., Ltd.<\/strong>, a China-based biopharmaceutical company, announced it has received <strong>marketing approval from the National Medical Products Administration (NMPA)<\/strong> for <strong>MY008211A<\/strong> as a treatment for <strong>adult patients with paroxysmal nocturnal hemoglobinuria (PNH)<\/strong> who have not previously received complement inhibitor therapy. MY008211A, a <strong>Category 1 drug<\/strong> developed by Createrna, represents the <strong>first home-grown oral complement factor B (CFB) inhibitor<\/strong> approved in China.<\/p>\n\n\n\n<h2 id=\"h-regulatory-approval-details\" class=\"wp-block-heading\">Regulatory Approval Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Regulatory Body<\/strong><\/td><td>National Medical Products Administration (NMPA), China<\/td><\/tr><tr><td><strong>Drug Name<\/strong><\/td><td>MY008211A (Lanocopan Hydrochloride Tablets)<\/td><\/tr><tr><td><strong>Classification<\/strong><\/td><td>Category 1 innovative drug<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Adult PNH patients without prior complement inhibitor therapy<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Oral complement factor B (CFB) inhibitor<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td>First domestically developed oral CFB inhibitor approved in China<\/td><\/tr><tr><td><strong>Approval Basis<\/strong><\/td><td>Phase III clinical trial vs. eculizumab<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-clinical-trial-results-phase-iii-study\" class=\"wp-block-heading\">Clinical Trial Results \u2013 Phase III Study<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>MY008211A<\/th><th>Eculizumab<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td><strong>Primary Endpoint: Hemoglobin Normalization (Hb \u2265 120 g\/L)<\/strong><\/td><td>50.0%<\/td><td>9.1%<\/td><td><strong>Superiority demonstrated<\/strong><\/td><\/tr><tr><td><strong>Study Design<\/strong><\/td><td>Multicenter, randomized, open-label, active-controlled<\/td><td>Same trial<\/td><td>Head-to-head comparison<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>PNH patients without prior complement inhibitor therapy<\/td><td>Same population<\/td><td>Treatment-na\u00efve cohort<\/td><\/tr><tr><td><strong>Secondary Endpoints<\/strong><\/td><td>Anemia improvement, hemolysis control, transfusion independence, quality of life<\/td><td>Same measures<\/td><td><strong>Superior across all endpoints<\/strong><\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Favorable and manageable<\/td><td>Established safety profile<\/td><td>Comparable tolerability<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The <strong>40.9 percentage point difference<\/strong> in hemoglobin normalization rates represents a clinically significant advantage over the current standard of care.<\/p>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> MY008211A (Lanocopan Hydrochloride) \u2013 <strong>oral complement factor B (CFB) inhibitor<\/strong><\/li>\n\n\n\n<li><strong>Innovation:<\/strong> <strong>First-in-class<\/strong> oral CFB inhibitor developed domestically in China<\/li>\n\n\n\n<li><strong>Target:<\/strong> Complement factor B, a key component of the alternative complement pathway<\/li>\n\n\n\n<li><strong>Advantage over Current Therapy:<\/strong> Oral administration vs. intravenous eculizumab injections every 2 weeks<\/li>\n\n\n\n<li><strong>Development Status:<\/strong> Now approved for marketing in China; potential for international expansion<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-competitive-landscape\" class=\"wp-block-heading\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Current Standard (Eculizumab)<\/th><th>MY008211A (Createrna)<\/th><\/tr><\/thead><tbody><tr><td><strong>Administration<\/strong><\/td><td>Intravenous infusion every 2 weeks<\/td><td>Oral tablet (daily)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>C5 inhibitor<\/td><td>Complement factor B inhibitor<\/td><\/tr><tr><td><strong>Efficacy (Hb \u2265 120 g\/L)<\/strong><\/td><td>9.1%<\/td><td>50.0%<\/td><\/tr><tr><td><strong>Convenience<\/strong><\/td><td>Requires clinic visits<\/td><td>Home administration<\/td><\/tr><tr><td><strong>Cost<\/strong><\/td><td>High (orphan drug pricing)<\/td><td>Potentially more accessible<\/td><\/tr><tr><td><strong>Market Access<\/strong><\/td><td>Global approval<\/td><td>China approval (first market)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>PNH Market Size:<\/strong> Rare disease affecting approximately <strong>1-2 per million people<\/strong> globally, but represents a high-value orphan drug indication<\/li>\n\n\n\n<li><strong>Current Treatment Burden:<\/strong> Eculizumab requires lifelong bi-weekly IV infusions, creating significant patient burden and healthcare system costs<\/li>\n\n\n\n<li><strong>Commercial Opportunity:<\/strong> Oral administration combined with superior efficacy could rapidly capture market share in China&#8217;s PNH patient population<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Domestic Innovation Milestone:<\/strong> Demonstrates China&#8217;s growing capability to develop first-in-class therapies for rare diseases<\/li>\n\n\n\n<li><strong>Orphan Drug Strategy:<\/strong> Success in PNH validates Createrna&#8217;s approach to targeting high-unmet-need rare disease indications<\/li>\n\n\n\n<li><strong>International Potential:<\/strong> Strong Phase III data may support regulatory submissions in other markets<\/li>\n\n\n\n<li><strong>Platform Validation:<\/strong> CFB inhibition approach could be extended to other complement-mediated diseases<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding commercial potential, market opportunities, and future development plans. Actual results may differ due to risks including market adoption, competitive dynamics, and regulatory requirements in other jurisdictions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Wuhan Createrna Science and Technology Co., Ltd., a China-based biopharmaceutical company, announced it has received&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[4795,15],"class_list":["post-68091","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-createrna-science-and-technology","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Createrna&#039;s MY008211A Becomes China&#039;s First Home-Grown Oral CFB Inhibitor Approved for Paroxysmal Nocturnal Hemoglobinuria - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Wuhan Createrna Science and Technology Co., Ltd., a China-based biopharmaceutical company, announced it has received marketing approval from the National Medical Products Administration (NMPA) for MY008211A as a treatment for adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received complement inhibitor therapy. MY008211A, a Category 1 drug developed by Createrna, represents the first home-grown oral complement factor B (CFB) inhibitor approved in China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68091\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Createrna&#039;s MY008211A Becomes China&#039;s First Home-Grown Oral CFB Inhibitor Approved for Paroxysmal Nocturnal Hemoglobinuria\" \/>\n<meta property=\"og:description\" content=\"Wuhan Createrna Science and Technology Co., Ltd., a China-based biopharmaceutical company, announced it has received marketing approval from the National Medical Products Administration (NMPA) for MY008211A as a treatment for adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received complement inhibitor therapy. MY008211A, a Category 1 drug developed by Createrna, represents the first home-grown oral complement factor B (CFB) inhibitor approved in China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68091\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-12T12:20:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-12T12:20:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68091#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68091\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Createrna&#8217;s MY008211A Becomes China&#8217;s First Home-Grown Oral CFB Inhibitor Approved for Paroxysmal Nocturnal Hemoglobinuria\",\"datePublished\":\"2026-06-12T12:20:17+00:00\",\"dateModified\":\"2026-06-12T12:20:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68091\"},\"wordCount\":499,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Createrna Science and Technology\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68091#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68091\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68091\",\"name\":\"Createrna's MY008211A Becomes China's First Home-Grown Oral CFB Inhibitor Approved for Paroxysmal Nocturnal Hemoglobinuria - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-12T12:20:17+00:00\",\"dateModified\":\"2026-06-12T12:20:18+00:00\",\"description\":\"Wuhan Createrna Science and Technology Co., Ltd., a China-based biopharmaceutical company, announced it has received marketing approval from the National Medical Products Administration (NMPA) for MY008211A as a treatment for adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received complement inhibitor therapy. MY008211A, a Category 1 drug developed by Createrna, represents the first home-grown oral complement factor B (CFB) inhibitor approved in China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68091#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68091\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68091#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Createrna&#8217;s MY008211A Becomes China&#8217;s First Home-Grown Oral CFB Inhibitor Approved for Paroxysmal Nocturnal Hemoglobinuria\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Createrna's MY008211A Becomes China's First Home-Grown Oral CFB Inhibitor Approved for Paroxysmal Nocturnal Hemoglobinuria - Insight, China&#039;s Pharmaceutical Industry","description":"Wuhan Createrna Science and Technology Co., Ltd., a China-based biopharmaceutical company, announced it has received marketing approval from the National Medical Products Administration (NMPA) for MY008211A as a treatment for adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received complement inhibitor therapy. MY008211A, a Category 1 drug developed by Createrna, represents the first home-grown oral complement factor B (CFB) inhibitor approved in China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68091","og_locale":"en_US","og_type":"article","og_title":"Createrna's MY008211A Becomes China's First Home-Grown Oral CFB Inhibitor Approved for Paroxysmal Nocturnal Hemoglobinuria","og_description":"Wuhan Createrna Science and Technology Co., Ltd., a China-based biopharmaceutical company, announced it has received marketing approval from the National Medical Products Administration (NMPA) for MY008211A as a treatment for adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received complement inhibitor therapy. MY008211A, a Category 1 drug developed by Createrna, represents the first home-grown oral complement factor B (CFB) inhibitor approved in China.","og_url":"https:\/\/flcube.com\/?p=68091","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-12T12:20:17+00:00","article_modified_time":"2026-06-12T12:20:18+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68091#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68091"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Createrna&#8217;s MY008211A Becomes China&#8217;s First Home-Grown Oral CFB Inhibitor Approved for Paroxysmal Nocturnal Hemoglobinuria","datePublished":"2026-06-12T12:20:17+00:00","dateModified":"2026-06-12T12:20:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68091"},"wordCount":499,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Createrna Science and Technology","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68091#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68091","url":"https:\/\/flcube.com\/?p=68091","name":"Createrna's MY008211A Becomes China's First Home-Grown Oral CFB Inhibitor Approved for Paroxysmal Nocturnal Hemoglobinuria - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-12T12:20:17+00:00","dateModified":"2026-06-12T12:20:18+00:00","description":"Wuhan Createrna Science and Technology Co., Ltd., a China-based biopharmaceutical company, announced it has received marketing approval from the National Medical Products Administration (NMPA) for MY008211A as a treatment for adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received complement inhibitor therapy. MY008211A, a Category 1 drug developed by Createrna, represents the first home-grown oral complement factor B (CFB) inhibitor approved in China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68091#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68091"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68091#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Createrna&#8217;s MY008211A Becomes China&#8217;s First Home-Grown Oral CFB Inhibitor Approved for Paroxysmal Nocturnal Hemoglobinuria"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68091","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68091"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68091\/revisions"}],"predecessor-version":[{"id":68092,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68091\/revisions\/68092"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68091"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68091"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68091"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}